Herbal medicine for the treatment of cardiovascular disease: Clinical considerations

Archives of Internal Medicine

Volumn 158, Issue 20, 1998, Pages 2225-2234

  Mashour, Nick H ^a   Lin, George I ^b   Frishman, William H ^c,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Department of Orthopaedic Surgery   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AESCULUS HIPPOCASTANUM EXTRACT; CARDIAC GLYCOSIDE; CARDIOVASCULAR AGENT; CHINESE DRUG; CRATAEGUS EXTRACT; DIGITALIS; DIGITOXIN; FLAVANOL DERIVATIVE; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; RAUWOLFIA ALKALOID; RESERPINE; ROSMARINUS OFFICINALIS EXTRACT; TETRANDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERATRUM ALKALOID;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; GARLIC; GINSENG; HEART ARRHYTHMIA; HEART PROTECTION; HERBAL MEDICINE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTOXICATION; MEDICAL PRACTICE; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; SALVIA MILTIORRHIZA; UNITED STATES; VOMITING;

ANGINA PECTORIS; ARRHYTHMIA; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; PHYTOTHERAPY; PLANT EXTRACTS; UNITED STATES; VENOUS INSUFFICIENCY;

EID: 0032501107     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.20.2225     Document Type: Review

References (125)

1. 2 agonist activity derived from ferulic acid, an active component of Ligusticum wallichii Franch. J Cardiovasc Pharmacol. 1998;31:750-757.
2. Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States. N Engl J Med. 1993;328:246-252.
3. Astin JA. Why patients use alternative medicine: results of a national study. JAMA. 1998; 279:1548-1553.
4. Ernst E: Harmless herbs? a review of the recent literature. Am J Med. 1998;104:170-178.
5. Tyler VE. Herbs of Choice: The Therapeutic Use of Phytomedicinals. New York, NY: Pharmaceutical Product Press; 1994.
6. Stuhlemmer U, Kreis W, Eisenbeiss M, Reinhard E. Cardiac glycosides in partly submerged shoots of Digitalis lanata. Planta Med. 1993;59:539-545.
7. Dickstein ES, Kunkel FW. Foxglove tea poisoning. Am J Med. 1980;69:167-169
8. Radford DJ, Gillies AD, Hinds JA, Duffy P. Naturally occurring cardiac glycosides. Med J Aust. 1986;144:540-544.
9. Cheung K, Hinds JA, Duffy P. Detection of poisoning by plant-origin cardiac glycoside with the Abbott Tdx analyzer. Clin Chem. 1989;35:295-297.
10. Moxley RA, Schneider NR, Steinegger DH, Carlson MP. Apparent toxicosis associated with lily-of-the-valley (Convallaria majalis) ingestion in a dog. J Am Vet Med Assoc. 1989;195:485-487.
11. Bossi M, Brambilla G, Cavilla A, et al. Threatening arrhythmia by uncommon digitalic toxicosis [in Italian]. G Ital Cardiol. 1981;11:2254-2257.
12. Hayes BE, Bessen HA, Wightman WD. Oleander tea: herbal draught of death. Ann Emerg Med. 1985;14:350-353.
13. Ansford AJ, Morris H. Fatal oleander poisoning. Med J Aust. 1981;1:360-361.
14. Shaw D, Pearn J. Oleander poisoning. Med J Aust. 1979;2:267-269.
15. Tumcok Y, Kozan O, Cadvar C, et al. Urginea maritima (squill) toxicity. J Toxicol Clin Toxicol. 1995; 33:83-86.
16. Bagrov AY, Roukoyatkina NI, Pinaev AG, Dmitrieva RI. Effects of two endogenous Na+, K(+)-ATPase inhibitors, marinobufagenin and ouabain, on isolated rat aorta. Eur J Pharmacol. 1995;274:151-158.
17. Nishoka SA, Resende ES. Transitory complete atrioventricular block associated to ingestion of Nerium oleander. Rev Assoc Med Bras. 1995;41:60-62.
18. Rich SA, Libera JM, Locke RJ. Treatment of fox-glove extract poisoning with digoxin-specific Fab fragments. Ann Emerg Med. 1993;22:1904-1907.
19. Safadi R, Levy I, Amitai Y, Caraco Y. Beneficial effect of digoxin-specific Fab antibody fragments in oleander intoxication. Arch Intern Med. 1995;155:2121-2125.
20. Galey FD, Holstege DM, Plumlee KH, et al. Diagnosis of oleander poisoning in livestock. J Vet Diagn Invest. 1996;8:358-364.
21. Langford SD, Boor PJ. Oleander toxicity: an examination of human and animal toxic exposure. Toxicology. 1996;109:1-13.
22. McRae S. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. CMAJ. 1996;155:293-295.
23. Geehr E. Common toxic plant ingestions. Emerg Med Clin North Am. 1984;2:553-563.
24. Litovitz TL, Clark LR, Soloway RA. 1993 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 1993;12:546-584.
25. Szabuniewicz M, McGrady JD, Camp BJ. Treatment of experimentally induced oleander poisoning. Arch Int Pharmcodyn. 1971;189:12-21.
26. Osterloh J, Herold S, Pond S. Oleander interference in the digoxin radioimmunoassay in a fatal ingestion. JAMA. 1982;247:1596-1597.
27. Oates JA. Antihypertensive agents and the drug therapy of hypertension. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill Book Co; 1996:781-808.
28. Rauwolfia alkaloids. USP DI: Drug Information for the Health Care Professional. Vol 1. 18th ed. Rockville, Md: US Pharmacopeial Convention; 1998:2486.
29. Physician's Desk Reference. 43rd ed. Montvale, NJ: Medical Economics Co; 1989:1648.
30. Brunton LL. Agents affecting gastrointestinal water flux, emesis and antiemetics, bile acids and pancreatic enzymes. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill Book Co; 1996:917-936.
31. Sutter MC, Wang YX. Recent cardiovascular drugs from Chinese medicinal plants. Cardiovasc Res. 1993;27:1891-1901.
32. Rossier MF, Python CP, Capponi AM, et al. Blocking T-type calcium channels with tetrandrine inhibits steroidogenesis in bovine adrenal glomerulosa cells. Endocrinology. 1993;132:1035-1043.
33. Kawashima K, Hayakawa T, Miwa Y, et al. Structure and hypotensive activity relationships of tetrandrine derivatives in stroke-prone spontaneously hypertensive rats. Gen Pharmacol. 1990; 21:343-347.
34. Vanherweghem JL. A new form of nephropathy secondary to the absorption of Chinese herbs [in French]. Bull Mem Acad R Med Belg. 1994;149: 128-135.
35. Schmeiser HH, Bieler CA, Wiessler M, Van Ypersele DE, Strihou C, Cosyns JP. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 1996;56:2025-2028.
36. Bieler CA, Stiborova M, Wiessler M, et al. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis. 1997;18:1063-1067.
37. Violin C. Belgian (Chinese herb) nephropathy: why? J Pharm Belg. 1997;52:7-27.
38. Ody P. The Complete Medicinal Herbal. New York, NY: Dorling Kindersley; 1993.
39. Kuramochi T, Chu J, Suga T. Gou-teng (from Uncaria rhynchophylla Miquel)-induced endothelium-dependent and -independent relaxations in the isolated rat aorta. Life Sci. 1994;54:2061-2069.
40. Jaffe AM, Gephardt D, Courtemanche L. Poisoning due to ingestion of Veratrum viride (false hellebore). J Emerg Med. 1990;8:161-167.
41. Quatrehomme G, Bertrand F, Chauvet C, Ollier A. Intoxication from Veratrum album. Hum Exp Toxicol. 1993;12:111-115.
42. Festa M, Andreeto B, Ballaris MA, Panio A, Piervittori R. Un caso di awelenamento da Veratro. Minerva Anestesiol. 1996;62:195-196.
43. Chiou W-F, Shum AY-C, Liao J-F, Chen C-F. Studies of the cellular mechanisms underlying the vasorelaxant effects of rutaecarpine, a bioactive component extracted from an herbal drug. J Cardiovasc Pharmacol. 1997;29:490-498.
44. Bahorun T, Trotin F, Pommery J, et al. Antioxidant activities of Crataegus monogyna extracts. Planta Med. 1994;60:323-328.
45. Vibes J, Lasserre B, Gleye J, et al. Inhibition of thromboxane A2 biosynthesis in vitro by the main components of Crataegus oxyacantha (Hawthorn) flower heads. Prostaglandins Leukot Essent Fatty Acids. 1994;50:173-175.
46. Shanthi S, Parasakthy K, Deepalakshmi PD, Devaraj SN. Hypolipidemic activity of tincture of Crataegus in rats. Indian J Biochem Biophys. 1994; 31:143-146.
47. Rajerdan S, Deepalakshmi PD, Parasakthy K, Devaraj H, Devaraj SN. Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet. Atherosclerosis. 1996;123:235-241.
48. Nasa Y, Hashizume H, Hoque AN, Abiko Y. Protective effect of Crataegus extract on the the cardiac mechanical dysfunction in isolated perfused working rat heart. Arzneimittelforschung. 1993;43:945-949.
49. Roddweig C, Hensel H. Reaction of local myocardial blood flow in nonanesthesized dogs and anesthesized cats to the oral and parenteral administration of a Crataegus fraction (oligomere procyanidines) [in German]. Arzneimittelforschung. 1977;27:1407-1410.
50. Taskov M. On the coronary and cardiotonic action of crataegus. Acta Physiol Pharmacol Bulg. 1997;3:53-57.
51. Blesken R. Crataegus in cardiology [in German]. Fortschr Med. 1992;110:290-292.
52. Petkov V. Plants and hypotensive, antiatheromatous and coronarodilating action. Am J Chin Med. 1979;7:197-236.
53. Weikl A, Assmus KD, Neukum-Schmidt A, et al. Crataegus special extract WS 1442: assessment of objective effectiveness in patients with heart failure (NYHA II). Fortschr Med. 1996;114:291-296.
54. Schussler M, Holzl J, Fricke U. Myocardial effects of flavonoids from Crataegus species. Arzneimittelforschung. 1995;45:842-845.
55. Joseph G, Zhao Y, Klaus W. Pharmacologic action profile of Crataegus extract in comparison to epinephrine, amirinone, milrinone, and digoxin in the isolated perfused guinea pig heart [in German]. Arzneimittelforschung. 1995;45:1261-1265.
56. Popping S, Rose H, Ionescu I, Fischer Y, Kammermeier H. Effect of a hawthorn extract on contraction and energy turnover of isolated rat cardiomyocytes. Arzneimittelforschung. 1995;45:1157-1161.
57. Mawrey DB. Herbal Tonic Therapies. New Canaan, Conn: Keats Publishing Inc; 1993.
58. Kwan CY. Vascular effects of selected antihypertensive drugs derived from traditional medicinal herbs. Clin Exp Pharmacol Physiol. 1995; 22:297-299.
59. Zhang W, Wojta J, Binder BR. Effect of notogin-senoside R1 on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 1994;14:1040-1046.
60. Lin SG, Zheng XL, Chen QY, Sun JJ. Effect of Panax notoginseng saponins on increased proliferation of cultured aortic smooth muscle cells stimulated by hypercholestoremic serum. Chung Kuo Yao Li Hsueh Pao. 1993;14:314-316.
61. Lei XL, Chiou GC. Cardiovascular pharmacology of Panax notoginseng (Burk) FH Chen and Salvia miltiorrhiza. Am J Chin Med. 1986;14:145-152.
62. Wang Z, Roberts JM, Grant PG, et al. The effect of a medicinal Chinese herb on platelet function. Thromb Haemost. 1982;48:301-306.
63. Yagi A, Fujimoto K, Tanonaka K, et al. Possible active components of tan-shen (Salvia miltiorrhiza) for protection of the myocardium against ischemia-induced derangements. Planta Med. 1989;55:51-54.
64. Zhao BL, Jiang W, Zhao Y, Hou JW, Xin WJ. Scavenging effects of Salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. Biochem Mol Biol Int. 1996;38:1171-1182.
65. Chan K, Lo AC, Yeung JH, Woo KS. The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. J Pharm Pharmacol. 1995;47:402-406.
66. Kleijnen J, Knipschild P, Ter Riet G. Garlic, onions and cardiovascular risk factors: a review of the evidence from human experiments with emphasis on commercially available preparations. Br J Clin Pharmacol. 1989;28:535-544.
67. Steiner M, Khan AH, Holbert D, Lin RI. A double-blind cross-over study in hypercholesterolemic men that compared the effect of aged garlic extract and placebo administration on blood lipids. Am J Clin Nutr. 1996;63:866-870.
68. Silagy CA, Neil HA. A meta-analysis of the effect of garlic on blood pressure. J Hypertens. 1994;12:463-468.
69. Silagy C, Neil A. Garlic as a lipid lowering agent: a meta-analysis. J R Coll Physicians Lond. 1994; 28:39-45.
70. Kendler BS. Garlic (Allium sativum) and onion (Allium cepa): a review of their relationship to cardiovascular disease. Prev Med. 1987;16:670-685.
71. Isaacsohn JL, Moser M, Stein EA, et al. Garlic powder and plasma lipids and lipoproteins: a multicenter, randonized, plcebo-controlled trial. Arch Intern Med. 1998;158:1189-1194.
72. Jain AK, Vargas R, Gotzkowsky S, McMahon FG. Can garlic reduce levels of serum lipids? a controlled clinical study. Am J Med. 1993;94:632-635.
73. Neil HA, Silagy CA, Lancaster T, et al. Garlic powder in the treatment of moderate hyperlipidae-mia: a controlled trial and meta-analyses. J R Coll Physicians Lond. 1996;30:329-334.
74. Simons LA, BalaSubramaniam S, Von Konigsmark M, Parfitt A, Simons J, Peters W. On the effect of garlic on plasma lipids and lipoproteins in mild hypercholesterolemia. Atherosclerosis. 1995;113:219-225.
75. Bordia A, Verma SK, Srivastava KC. Effect of garlic on platelet aggregation in humans: a study in healthy subjects and patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids. 1996;55:201-205.
76. Ali M, Thomson M. Consumption of a garlic clove a day could be beneficial in preventing thrombosis. Prostaglandins Leuko Essent Fatty Acids. 1995;53:211-212.
77. Breithaupt-Grogler K, Ling M, Boudoulas H, Beliz GG. Protective effect of chronic garlic intake on elastic properties of aorta in the elderly. Circulation. 1997;96:2649-2655.
78. Mader FH. Treatment of hyperlipidaemia with garlic powder tablets: evidence from the German Association of General Practitioners' Multicentric Placebo-Controlled Double-Blind Study. Arzneimittelforschung. 1990;40:1111-1116.
79. Delaney TA, Donnelley AM. Garlic dermatitis. Australas J Dermatol. 1996;37:109-110.
80. Rose KD, Croissant PD, Parliament CF, Levin MB. Spontaneous spinal epidural hematoma with associated liver dysfunction from excessive garlic ingestion: a case report. Neurosurgery. 1990;26:880-882.
81. Singh V, Kaul S, Chander R, Kapoor NK. Stimulation of low density lipoprotein receptor activity in liver membrane of guggulsterone treated rats. Pharmacol Res. 1990;22:37-44.
82. Nityanand S, Srivastava JS, Asthana OP. Clinical trials with gugulipid: a new hypolipidemic agent. J Assoc Physicians India. 1989;37:323-328.
83. Sing RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukulas an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther. 1994;8:654-664.
84. Dalvi SS, Nayak VK, Pohujani SM, Desai NK, Kshirsagar NA, Gupta KC. Effect of gugulipid on bioavailability of diltiazem and propranolol. J Assoc Physicians India. 1994;42:454-455.
85. Sundaram V, Hanna AN, Lubow GP, Koneru L, Falko JM, Sharma HM. Inhibition of low-density lipoprotein oxidation by oral herbal mixtures Maharishi Amrit Kalash-4 and Maharishi Amrit Kalash-5 in hyperlipidemic patients. Am J Med Sci. 1997;314:303-310.
86. Huxtable RJ. The pharmacology of extinction. J Ethnopharmacol. 1992;37:1-11.
87. Z'Brun A. Ginkgo: myth and reality [in German]. Schweiz Rundsch Med Prax. 1995;84:1-6.
88. Kleinjen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol. 1992; 34:352-358.
89. Allard M. Treatment of the disorders of aging with Ginkgo biloba extract [in French]. Presse Med. 1986;15:1540-1545.
90. LeBars PL, Katz MM, Berman N, et al, for the North American Study Group. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia JAMA. 1997;278:1327-1332.
91. Doly M, Droy-Lefaix MT, Braquet P. Oxidative stress in diabetic retina. EXS. 1992;62:299-307.
92. 2 determination. Angiology. 1994;45:413-417.
93. Tosaki A, Droy-Lefaix MT, Pali T, Das DK. Effects of SOD, catalase, and a novel antiarrhythmic drug, Egb 761, on reperfusion-induced arrhythmias in isolated rat hearts. Free Radic Biol Med. 1993;14:361-370.
94. Haramaki N, Aggarwal S, Kawabata T, Droy-Lefaix MT, Packer L. Effects of natural antioxidant EGb 761 on myocardial ischemia-reperfusion injury. Free Radic Biol Med. 1994;16:789-794.
95. Pietri S, Seguin JR, D'Arbigny P, Drieu K, Culcasi M. Egb 761 pretreatment limits free radical-induced oxidative stress in patients undergoing coronary bypass surgery. Cardiovasc Drugs Ther. 1997;11:121-131.
96. Offord EA, Mace K, Ruffieux C, et al. Rosemary components inhibit benzo[a]pyrene induced genotoxicity in human bronchial cells. Carcinogenesis. 1995;16:2057-2062.
97. Haraguchi H, Saito T, Okamura N, Yagi A. Inhibition of lipid peroxidation and superoxide generation by diterpenoids from Rosmarinus officinalis. Planta Med. 1995;61:333-336.
98. Larrondo JV, Agut M, Calvo-Torras MA. Antimicrobial activity of essences from labiates. Microbios. 1995;82:171-172.
99. Al-Hader AA, Hasan ZA, Aqel MB. Hyperglycemic and insulin release inhibitory effects of Rosmarinus officinalis. J Ethnopharmacol. 1994;43:217-221.
100. Swan AR, Dutton SP, Truswell AS. Salicylates in foods. J Am Diet Assoc. 1985;85:950-960.
101. Tyler VE. The Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. 3rd ed. New York, NY: Pharmaceutical Product Press; 1993.
102. Facino RM, Carini M, Stefani R, Aldini G, Saibene L. Anti-elastase and anti-hyaluronidase activities of saponins and sapogenins from Hedera helix, Aesculus hippocastanum, and Ruscus aculeatus: factors contributing to their efficacy in the treatment of venous insufficiency. Arch Pharm (Weinheim). 1995;328:720-724.
103. Guillaume M, Padioleau F. Veinotonic effect, vascular protection, antiinflammatory and free radical scavenging properties of horse chestnut extract. Arzneimittelforschung. 1994;44:25-35.
104. Rothkopf M, Vogel G. New findings on the efficacy and mode of action of the horse chestnut saponin escin [in German]. Arzneimittelforschung. 1976;26:225-235.
105. Diehm C, Vollbrecht, Amendt K, Comberg HU. Medical edema protection: clinical benefit in patients with chronic deep vein incompetence: a placebo controlled double-blind study. Vasa. 1992;21:188-192.
106. Bisler H, Pfeifer R, Kluken N, Pauschinger P. Effects of horse chestnut seed extract on transcapillary filtration in chronic venous insufficiency [in German]. Dtsch Med Wochenschr. 1986;111:1321-1329.
107. Diehm C, Trampisch HJ, Lange S, Schmidt C. Comparison of leg compression stocking and oral horse chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet. 1996; 347:292-294.
108. Greeske K, Pohlmann BK. Horse chestnut seed extract: an effective therapy principle in general practice: drug therapy in chronic venous insufficiency [in German]. Fortschr Med. 1996;114:196-200.
109. Schorr DM, Gruber UF. Prophylaxis of thromboembolic complications in gynecological surgery [in German]. Geburtshilfe Frauenheilkd. 1977;37:291-296.
110. Lang W. Studies on the percutaneous absorption of 3H-aescin in pigs. Res Exp Med (Berl). 1977;169:175-187.
111. Takegoshi K, Tohyama T, Okunda K, et al. A case of Venoplant-induced hepatic injury. Gastroenterol Jpn. 1986;21:62-65.
112. Voigt E, Junger H. Acute posttraumatic renal failure following therapy with antibiotics and beta-aescin [in German]. Anaesthesist. 1978;27:81-83.
113. Hellberg K, Ruschewski W, De Vivie R. Drug induced acute renal failure after heart surgery [in German]. Thoraxchir Vask Chir. 1975;23:396-399.
114. Lang W. Dialysability of aescin [in German]. Arzneimittelforschung. 1984;34:221-223.
115. Grob PJ, Muller-Schoop JW, Hacki MA, Joller-Jemelka HI. Drug-induced pseudolupus. Lancet. 1975;2:144-148.
116. Walli F, Grob PJ, Muller-Schoop J. Pseudo-(venocuran-) lupus: a minor episode in the history of medicine [in German]. Schweiz Med Wochenschr. 1981;111:1398-1405.
117. Bouskela E, Cyrino FZ, Marcelon G. Possible mechanisms for the inhibitory effect of Ruscus extract on increased microvascular permeability induced by histamine in hamster cheek pouch. J Cardiovasc Pharmacol. 1994;24:281-285.
118. Bouskela E, Cyrino FZ, Marcelon G. Possible mechanisms for the venular constriction elicited by Ruscus extract on hamster cheek pouch. J Cardiovasc Pharmacol. 1994;24:165-170.
119. Bouskela E, Cyrino FZ, Marcelon G. Effects of Ruscus extract on the internal diameter of arterioles and venules of the hamster cheek pouch microcirculation. J Cardiovasc Pharmacol. 1993; 22:221-224.
120. Berg D. Venous constriction by local administration of ruscus extract [in German]. Fortschr Med. 1990;108:473-476.
121. Berg D. Venous tonicity in pregnancy varicose veins [in German]. Fortschr Med. 1992;110:67-68,71-72.
122. Weindorf N, Schultz-Ehrenburg U. Controlled study of increasing venous tone in primary varicose veins by oral administration of Ruscus aculeatus and trimethylhespiridinchalcone [in German]. Z Hautkr. 1987;62:28-38.
123. Zhou ZY, Jin HD. Clinical Manual of Chinese Herbal Medicine. New York, NY: Churchill Livingstone Inc; 1997.
124. Chen ZY. Use of Xin Bao in the treatment of 87 patients with sick sinus syndrome. Chin Modern Develop Trad Med. 1990;10:529-531.
125. Jones TK, Lawson BM. Profound neonatal congestive heart failure caused by maternal concumption of blue cohosh herbal medication. J Pediatr. 1998;132:550-552.